Tirzepatide
Tirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor co-agonist that produces a 20.9 percent mean body weight reduction at 15 mg over 72 weeks (SURMOUNT-1, n=2,539, Jastreboff 2022) and a 6.5 percentage-point advantage over semaglutide 2.4 mg head-to-head (SURMOUNT-5, Wharton 2025). The class trade-off: 82.5 percent of users regain at least 25 percent of lost weight within a year of stopping (SURMOUNT-4).
Tirzepatide scored 6.0 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide.
What It Is
Type: Peptide pharmaceutical (dual GIP/GLP-1 agonist; prescription / gray-market).
Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is structurally modified with a C20 fatty acid chain that binds albumin and extends half-life to approximately 5 days, enabling once-weekly subcutaneous dosing. Eli Lilly developed tirzepatide under Lilly-proprietary peptide engineering; the FDA approved it for type 2 diabetes as Mounjaro in May 2022, for chronic weight management as Zepbound in November 2023, and for moderate-to-severe obstructive sleep apnea with obesity in June 2024.
Mechanistically, tirzepatide is qualitatively different from single-agonist GLP-1 receptor drugs like semaglutide and liraglutide. The GLP-1R arm drives glucose-dependent insulin secretion from pancreatic beta cells, suppresses postprandial glucagon, delays gastric emptying by approximately 50 to 70 percent at steady state, and reduces appetite via vagal and central hypothalamic signaling. The GIPR arm adds independent central satiety signaling, direct effects on adipocyte biology that favor metabolically healthier subcutaneous fat storage over visceral accumulation, glucoprotective glucagon stimulation during hypoglycemia, and possible preadipocyte differentiation toward brown or beige phenotype in preclinical rodent work. The net result is a 44 percent visceral adipose tissue reduction vs 3 percent for insulin comparator at 52 weeks (SURPASS-3 MRI substudy), a 20.9 percent mean body weight reduction at 15 mg over 72 weeks in non-diabetic obesity, and HbA1c reductions in type 2 diabetes that exceed every non-insulin comparator tested.
The clinical evidence base is unusually broad for a drug launched in 2022. Phase 3 data spans weight loss in non-diabetic obesity (SURMOUNT-1), weight loss in type 2 diabetes (SURMOUNT-2), lifestyle-combined weight loss (SURMOUNT-3), rebound and maintenance (SURMOUNT-4), direct head-to-head vs semaglutide (SURMOUNT-5), obstructive sleep apnea (SURMOUNT-OSA), glycemic control in T2D monotherapy through add-on therapy (SURPASS-1 through SURPASS-5), cardiovascular outcomes (SURPASS-CVOT), and biopsy-confirmed metabolic dysfunction-associated steatohepatitis histology (SYNERGY-NASH). Total enrollment across pivotal trials exceeds 25,000 participants. The limitation: every pivotal trial is Eli Lilly-sponsored, and no independent replication at comparable scale has been published. Real-world effectiveness registry data replicates trial findings within approximately 15 percent.
Current status: Haven't personally tried. Researching actively.
Terminology
- AHI: Apnea-Hypopnea Index. Measure of obstructive sleep apnea severity: events per hour of sleep. Normal under 5, mild 5-14, moderate 15-29, severe 30+.
- CV / MACE: Cardiovascular / Major Adverse Cardiovascular Events. MACE is typically the composite of CV death, nonfatal myocardial infarction, and nonfatal stroke.
- CVOT: Cardiovascular Outcomes Trial. Post-marketing trial required by FDA for many diabetes drugs.
- DEXA: Dual-Energy X-ray Absorptiometry. Body composition scan measuring fat mass, lean mass, and bone density.
- FAERS: FDA Adverse Event Reporting System. Public database of post-market safety reports.
- GIP / GIPR: Glucose-dependent insulinotropic polypeptide / its receptor. The dominant incretin hormone in healthy individuals.
- GLP-1 / GLP-1R: Glucagon-like peptide-1 / its receptor. The incretin target of semaglutide and liraglutide.
- HbA1c: Glycated hemoglobin. A 2 to 3 month average of blood glucose. Normal under 5.7%, prediabetes 5.7-6.4%, diabetes 6.5%+.
- HF: Heart Failure.
- HR: Hazard Ratio. Relative risk metric in survival analyses. HR 0.85 means 15% relative risk reduction.
- MASH / MASLD: Metabolic dysfunction-Associated Steatohepatitis / Steatotic Liver Disease. Renamed from NASH/NAFLD in 2023.
- MEN 2: Multiple Endocrine Neoplasia type 2. Hereditary syndrome predisposing to medullary thyroid carcinoma.
- MRI-PDFF: Magnetic Resonance Imaging Proton Density Fat Fraction. Non-invasive liver fat quantification.
- MTC: Medullary Thyroid Carcinoma. The rare C-cell thyroid cancer flagged in the tirzepatide black-box warning.
- NEJM: New England Journal of Medicine.
- NNT: Number Needed to Treat. 1/absolute risk difference.
- OSA: Obstructive Sleep Apnea.
- PAP: Positive Airway Pressure. The CPAP/BiPAP machines used as first-line OSA therapy.
- SASP: Senescence-Associated Secretory Phenotype. Inflammatory signaling from senescent cells.
- SC: Subcutaneous. Injection route for tirzepatide.
- SGLT2i: Sodium-Glucose Co-transporter 2 inhibitors (e.g., empagliflozin, dapagliflozin).
- SURMOUNT: The Phase 3 tirzepatide obesity program.
- SURPASS: The Phase 3 tirzepatide type 2 diabetes program.
- T2D: Type 2 Diabetes Mellitus.
- Tmax: Time to maximum plasma concentration.
- VAT: Visceral Adipose Tissue.
- WC: Waist Circumference.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| subcutaneous | autoinjector pen (2.5, 5, 7.5, 10, 12.5, 15 mg) | 2.5-15 mg once weekly | 0.125-20 mg once weekly |
| subcutaneous | compounded vial (multi-dose) | N/A | 2.5-15 mg once weekly |
Protocols
Standard FDA titration Clinical
- Dose
- 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg
- Frequency
- Once weekly
- Duration
- ~20 weeks to reach 15 mg; indefinite thereafter
Matches SURMOUNT-1 protocol. Each step 4 weeks. Dose escalation conditional on tolerability. Nausea and vomiting peak in transition weeks
Community maintenance Anecdotal
- Dose
- 10-12.5 mg
- Frequency
- Once weekly
- Duration
- Indefinite
Biohacker consensus holds that 10-15 mg curve shows diminishing weight-loss returns with increased GI burden. De-escalation from 15 mg is common once target weight achieved
Biohacker microdose Anecdotal
- Dose
- 0.125-2.5 mg
- Frequency
- Once weekly
- Duration
- Cycled per user goals
Zero RCT support. Used for body recomposition, appetite modulation without aggressive weight loss, or alcohol craving management. Bryan Johnson trial: 3 weeks, discontinued due to +7% resting HR
SURMOUNT-OSA sleep apnea Clinical
- Dose
- 15 mg target
- Frequency
- Once weekly
- Duration
- 52 weeks in trial
AHI -25.3 events/hour; 51.5% moderate-severe OSA resolution in non-PAP arm
Lean-mass preservation stack Anecdotal
- Dose
- Baseline tirzepatide + 1.8-2.4 g/kg protein + resistance training 3-5x/wk + creatine 5g + HMB 3g
- Frequency
- Continuous during drug
- Duration
- Ongoing
Drops lean mass loss from ~25% of total weight loss to ~18%. Essential for adults over 50 due to bone and muscle signal
How this score is calculated →
Upside (3.33 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 5.0 | 1.250 | |
| Breadth of Benefits | 15% | 4.7 | 0.705 | |
| Evidence Quality | 25% | 4.5 | 1.125 | |
| Speed of Onset | 10% | 4.2 | 0.420 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 4.5 | 0.675 | |
| Total | 4.325 |
Upside Rationale
Efficacy (5.0/5.0): Tirzepatide achieves the largest weight-loss effect size of any approved pharmacotherapy. Jastreboff 2022 (SURMOUNT-1) documented -20.9 percent mean body weight reduction at 15 mg over 72 weeks (n=2,539; 57 percent achieving ≥20 percent loss, 74 percent ≥15 percent) vs -3.1 percent placebo. SURMOUNT-5 (Wharton 2025, n=751) showed a 6.5 percentage-point absolute advantage over semaglutide 2.4 mg at 72 weeks (-20.2 vs -13.7 percent pooled), with 31.6 vs 16.1 percent achieving ≥25 percent loss; this is non-surgical weight-loss territory approaching bariatric surgery magnitudes. SURPASS-2 (n=1,879) produced HbA1c reductions of -2.46 percentage points vs semaglutide 1.0 mg at -1.86 (Frias 2021). SURPASS-CVOT (n=13,884 T2D + CV risk) delivered a MACE HR of 0.85, all-cause mortality HR 0.87, and a standout heart-failure hospitalization HR of 0.71 over 3.4 years. SYNERGY-NASH achieved 62 percent histologic MASH resolution at 15 mg vs 10 percent placebo, the hardest endpoint in liver medicine. SURMOUNT-OSA eliminated moderate-to-severe OSA in 51.5 percent of non-PAP patients. Cohen's d substantially exceeds 1.0 on every primary endpoint; NNT under 3 for multiple outcomes. This is the maximum score on the Efficacy dimension, reserved for truly transformative interventions.
Breadth of Benefits (4.7/5.0): Tirzepatide touches cardiovascular (MACE reduction, HF hospitalization, lipids, BP), metabolic (HbA1c, insulin sensitivity, waist circumference, visceral fat), hepatic (MASH histologic resolution and fibrosis improvement), respiratory (OSA AHI reduction), gastrointestinal (mixed: severe early side effects, but reduced NAFLD), and behavioral-neural (71 percent of 1,580 Reddit posts report alcohol-craving reduction; early AUD RCTs underway). Three FDA-approved indications as of 2024 (T2D, obesity, OSA) with a fourth (MASH) expected. It does not meaningfully address cognition, immune function, or musculoskeletal performance beyond weight-loss-mediated secondary effects. The scope is specifically metabolic-cardiovascular-hepatic-respiratory with collateral behavioral benefits. Among approved pharmaceuticals, this breadth is near-maximal; among all interventions (including whole-body systemic compounds like creatine or taurine), it sits one step below.
Evidence Quality (4.5/5.0): Ten-plus Phase 3 RCTs with total enrollment exceeding 25,000 participants; FDA approval for three distinct indications; SURPASS-CVOT as a positive hard-outcome cardiovascular trial; SYNERGY-NASH as a positive histologic MASH trial (hardest liver endpoint); SURMOUNT-OSA as a positive sleep apnea trial. Active-comparator trials included (semaglutide, insulin glargine, insulin degludec). EMA, MHRA, and Health Canada approved. Two independent meta-analyses (Shi 2022, Dahl 2023) confirm tirzepatide ranks first-in-class on HbA1c and weight. Real-world effectiveness data replicates trial estimates within ~15 percent. The -0.5 adjustment reflects industry-only funding pattern and absent independent Phase 3 replication, not evidence-quality weakness: the hard-outcome data (CV mortality, liver histology, sleep apnea) is tier-1 regardless of funding source. NIH-funded SURMOUNT REAL is underway and may close this gap.
Speed of Onset (4.2/5.0): Appetite reduction is subjectively measurable within 1 to 2 weeks of first dose (even at the sub-therapeutic 2.5 mg starter). HbA1c reduction becomes statistically significant within 4 weeks. Postprandial glucose excursion improves within 1 week via gastric emptying delay. Weight-loss trajectory runs approximately 1 percent body weight per 2 weeks at target dose during weeks 12 through 36, after which the curve decelerates. Approximately 75 percent of total SURMOUNT-1 weight loss occurred in the first 36 weeks. Cardiovascular benefits require chronic dosing and accrue over years per SURPASS-CVOT's 3.4-year observation window. The onset is fast for metabolic endpoints, moderate for body composition, and slow for hard cardiovascular outcomes.
Durability (1.5/5.0): The single weakest upside dimension and the reason this intervention does not reach Strong Recommend tier despite exceptional efficacy. SURMOUNT-4 (Aronne 2023) demonstrated that the placebo-switched arm regained +14 percent body weight over 52 weeks with 82.5 percent regaining at least 25 percent of lost weight. Community reports consistently describe faster cold-stop rebound, with up to two-thirds regained within 90 days and ghrelin overshoot above baseline producing worse-than-pretreatment appetite. Cardiometabolic benefits (HbA1c, blood pressure, lipids) reverse proportionally. No reset signal exists: tirzepatide suppresses the metabolic physiology, it does not reprogram it. Chronic lifetime therapy is the realistic use model. This anchors durability at 1.5, well below semaglutide-class durability reference points and far below supplements like creatine or taurine that are mostly reversible without catastrophic rebound.
Bioindividuality Upside (4.5/5.0): Responder rates are unusually high. SURMOUNT-1 showed 85 to 91 percent of participants achieving ≥5 percent weight loss across the 5 to 15 mg dose range, 30 to 57 percent achieving ≥20 percent loss. In the approved-pharmaceutical universe, these responder rates sit in the top 5 percent of any drug. Early-weeks weight loss (≥5 percent at week 12) is the strongest predictor of week-72 outcome, providing a practical responder test. Higher baseline insulin resistance predicts greater response. Baseline BMI does not predict worse response, unlike many obesity interventions. Sex effects are minor (women lose more absolute kg but similar percent). Prediabetic participants reverted to normoglycemia at 95.3 percent in SURMOUNT-1. Genetic predictors in GLP1R and GIPR are emerging but not clinically validated. The non-responder fraction is small (~9 to 15 percent) and the drug works across a wide metabolic phenotype spectrum.
Downside (3.07 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.3 | 0.495 | |
| Financial Cost | 5% | 3.8 | 0.190 | |
| Time/Effort Burden | 5% | 1.8 | 0.090 | |
| Opportunity Cost | 5% | 2.2 | 0.110 | |
| Dependency / Withdrawal | 15% | 4.0 | 0.600 | |
| Reversibility | 25% | 2.3 | 0.575 | |
| Total | 3.260 | |||
| Harm subtotal × 1.4 | 4.018 | |||
| Opportunity subtotal × 1.0 | 0.390 | |||
| Combined downside | 4.408 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 3.068 |
Downside Rationale
Safety Risk (4.0/5.0): Catastrophic-risk floor triggered at 4.0, not higher. Hemorrhagic and necrotizing pancreatitis with confirmed fatal post-market cases is an intrinsic listed adverse event in the USPI postmarketing section. FAERS reports through Q1 2025 total 65,974, with 221 confirmed deaths (0.3 percent of known-outcome reports, comparable to many chronic pharmaceuticals). Sodhi et al. 2023 JAMA documented a 9.09x relative risk for pancreatitis and 3.67x for gastroparesis vs bupropion-naltrexone. A rodent-derived C-cell thyroid tumor black-box warning applies to the entire GLP-1 class; no confirmed human medullary thyroid carcinoma case in 4 years of wide exposure, but the 10-to-20-year latency means current data cannot exclude the risk. Real-world TriNetX cohort flagged elevated osteoporosis and fracture risk vs other GLP-1RAs. Ileus, intestinal obstruction, and bowel-obstruction lawsuits aggregated in MDL-3094 (Eastern District Pennsylvania, 1,521 Lilly cases) allege failure-to-warn. Six absolute contraindications: personal or family MTC, MEN 2, prior pancreatitis, severe gastroparesis, active inflammatory bowel disease, pregnancy or planned pregnancy. Scored at the floor minimum of 4.0 rather than higher because the absolute death rate remains below most chronic pharmaceuticals at equivalent exposure, and the MTC signal has yet to materialize in humans.
Side Effect Profile (3.3/5.0): Nausea occurs in 40 to 60 percent of users during titration, vomiting 15 to 25 percent, diarrhea 15 to 20 percent, constipation 15 to 20 percent. FAERS top reports: nausea (7,678), injection-site pain (9,849), vomiting, constipation, fatigue. Side effects peak in weeks 5 through 12 during dose escalation and attenuate meaningfully with adaptation. Long-term discontinuation-for-AE rate in SURMOUNT and SURPASS trials is in the single digits; most users who start finish. Injection-site reactions are common but mild. Unlabeled disproportionality signals include food-craving rebound, injection-site paresthesia, and elevated thyroid hormones without confirmed clinical sequelae. Fatigue is under-appreciated and community-reported at meaningful frequency during rapid weight loss. Scored 3.3 because frequency is high during titration but severity is manageable and tolerance develops in the large majority of users.
Financial Cost (3.8/5.0): LillyDirect (direct-to-consumer vial program) at $299 to $499 per month is the pragmatic tier since the FDA ended the compounding shortage exemption. Retail brand Mounjaro or Zepbound costs $1,000 to $1,300 per month without insurance. Compounded 503A tirzepatide from licensed pharmacies runs $200 to $500 per month in a legal gray area. Commercial insurance coverage is expanding rapidly; Medicare remains a coverage gap for Zepbound. Lifetime treatment at $299 per month LillyDirect is approximately $110,000 over 30 years, though for the indicated population this ROI compares favorably to bariatric surgery, T2D complications, and CV event costs. Generic tirzepatide is 5 to 8 years out post-patent.
Time/Effort Burden (1.8/5.0): Weekly subcutaneous injection is trivial once past the initial 20-week titration. Refrigeration required (2-8 C), with up to 30 days permitted at ≤30 C for travel. No meal-timing restriction. No blood-glucose monitoring required for non-diabetic users. The titration schedule is the main burden: roughly 20 weeks to reach 15 mg, during which dose changes are paired with pharmacy pickups and tolerability checks. After titration, maintenance involves under 5 minutes per week.
Opportunity Cost (2.2/5.0): For the indicated population (BMI ≥30, T2D, MASH, severe OSA, high CV risk), the opportunity cost of not using tirzepatide is measured in life-years lost, CV events, and preventable complications. For that population, tirzepatide is replacing disease progression, not exercise. For metabolically-healthy adults with 10 to 30 pounds to lose, the opportunity cost inverts: tirzepatide crowds out lifestyle-first approaches, muscle-mass preservation requires aggressive counter-measures, and the lifetime-drug commitment rarely justifies the rebound risk at that weight range. Stack compatibility with metformin is well-documented and often synergistic; with testosterone replacement in clinical practice; anecdotally with CJC-1295/ipamorelin for lean-mass preservation and BPC-157/TB-500 for GI and connective tissue support in the community "Wolverine Stack." Pregnancy and planned pregnancy are absolute exclusions. Resistance-training performance may degrade acutely during GI-intensive titration.
Dependency/Withdrawal (4.0/5.0): SURMOUNT-4 establishes rapid weight rebound (+14 percent body weight in 52 weeks; 82.5 percent regain ≥25 percent of lost weight). Community anecdotal reports describe ghrelin overshoot above baseline, appetite rebound worse than pre-treatment, and up to two-thirds regain within 90 days cold-stop. Taper protocols are strongly preferred over abrupt cessation in clinical practice. The physiological dependency is not addictive in the classical neurochemical sense (no reinforcement signaling, no withdrawal syndrome beyond hunger) but functional dependency is high: the weight-loss benefit is entirely on-drug, and discontinuation reliably returns the user to near-baseline within a year.
Reversibility (2.3/5.0): Pharmacological reversal is clean: no drug residue, no permanent receptor changes, no metabolic programming effects. Weight regain, HbA1c rebound, and blood pressure reversal follow predictable trajectories described above. The two dimensions that may not fully reverse: lean mass loss (~10.9 percent absolute reduction from baseline in SURMOUNT-1 DEXA subset without resistance training) and bone density loss (TriNetX real-world cohort shows osteoporosis and fracture signal even after discontinuation). Full lean-mass recovery is possible with sustained resistance training but is neither automatic nor quick. Scored 2.3 to reflect the clean pharmacologic stop tempered by partial lean-mass and bone irreversibility.
Verdict
✅ Best for: Adults with BMI ≥35 where time-to-intervention-effect genuinely matters (obesity complications progressing despite lifestyle effort); type 2 diabetics with HbA1c above 8 percent failing metformin and SGLT2 inhibitors; biopsy-confirmed MASH with F2 to F3 fibrosis facing liver-outcome progression; moderate-to-severe obstructive sleep apnea resistant to or unable to tolerate PAP therapy; high-cardiovascular-risk T2D patients targeting MACE reduction per SURPASS-CVOT; adults with treatment-resistant obesity where SURMOUNT-5 weight-loss superiority over semaglutide is clinically meaningful. Also a rational choice for people who have intellectually accepted the chronic-therapy model and paired tirzepatide with aggressive resistance training, 1.8 to 2.4 g/kg protein, creatine, and HMB to preserve lean mass.
❌ Avoid if: Personal or family history of medullary thyroid carcinoma or MEN 2 (absolute contraindication per black box); any prior pancreatitis regardless of cause; severe gastroparesis or active inflammatory bowel disease; pregnancy or planned pregnancy within 2 months; type 1 diabetes; on oral contraceptives without willingness to switch to non-oral method (59 to 66 percent peak concentration reduction causes contraceptive failure); adults over 60 with osteoporosis or existing sarcopenia given the bone-loss and lean-mass signals; anyone seeking a short-term "detox" or "reset" (the SURMOUNT-4 rebound makes this impossible); anyone sourcing from gray-market Chinese research peptide suppliers given the ~70 percent contamination rate in independent testing. Also a poor fit for users with 15 to 30 pounds to lose who have not attempted a serious resistance-training plus protein-targeted dietary protocol first: the lifetime-drug cost and rebound profile rarely justify pharmaceutical intervention at that weight range.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Blood Sugar / Glycemic Control | 9.2 | SURPASS-1 HbA1c -2.07 pp monotherapy; 96% reaching <7% at 15 mg; class-leading glucose reduction outside insulin |
| ✅ Body Composition / Fat Loss | 9.0 | SURMOUNT-1 -20.9% at 15 mg, n=2,539, 72 weeks; SURMOUNT-5 head-to-head superior to semaglutide 2.4 mg |
| ✅ Metabolic Health | 8.7 | Touches all 5 metabolic-syndrome components: WC -19.6 cm, TG -27.5%, SBP -7.0 mmHg, HDL +10-15%, glucose |
| ✅ Liver / Detoxification | 8.3 | SYNERGY-NASH: 62% MASH resolution at 15 mg, 51% fibrosis ≥1 stage improvement; -52% MRI-PDFF liver fat |
| ✅ Sleep Quality | 8.0 | SURMOUNT-OSA: AHI -25.3 events/hour; 51.5% OSA resolution non-PAP; driven by weight loss reducing pharyngeal collapsibility |
| 💪 Cardiovascular | 7.8 | SURPASS-CVOT: MACE HR 0.85, HF hospitalization HR 0.71, all-cause mortality HR 0.87 over 3.4 years |
| 💪 Healthspan | 7.0 | Reduces CV events, MASH, OSA, body weight; long-term bone and sarcopenia signal offsets |
| 👍 Fertility (Female) | 6.8 | PCOS-adjacent improvements plausible via weight loss and insulin sensitivity; no dedicated fertility RCT yet |
| 👍 Longevity / Lifespan | 6.5 | SURPASS-CVOT all-cause mortality HR 0.87 over 3.4 years; mechanistic plausibility via metabolic improvement; no dedicated longevity RCT |
| 👍 Anti-Inflammatory | 6.2 | CRP and inflammatory marker reductions secondary to weight loss; no direct anti-inflammatory mechanism |
| 👍 Energy / Fatigue | 6.2 | Community reports improved daytime energy secondary to weight loss and glucose stability; no direct energy measurement |
| 👍 Fertility (Male) | 6.0 | Secondary to weight-loss testosterone normalization in obese men; no direct RCT |
| 👍 Sleep Architecture (Deep/REM) | 5.8 | Indirect via AHI reduction and body-weight effect; no polysomnography-specific architecture data |
| 👍 Libido / Sexual Health | 5.8 | Improved in men via T2D improvement and weight-related testosterone recovery; no primary RCT |
| ⚖️ Depression | 5.7 | Real-world cohort shows lower suicide risk vs other anti-obesity agents; indirect via weight loss |
| ⚖️ Endurance / Cardio | 5.5 | Improved aerobic capacity secondary to weight loss; loss of muscle may reduce maximal power |
| ⚖️ Cognition / Focus | 5.2 | Observational dementia-risk reduction signal (confounded); no primary cognition RCT completed |
| ⚖️ Neuroprotection | 5.2 | GLP-1R CNS expression and preclinical neuroprotection; no human RCT endpoint |
| ⚖️ Mood / Emotional Regulation | 5.2 | FDA removed suicidality warning; observational data neutral-to-positive mood signal |
| ⚖️ Stress / Resilience | 5.0 | Weight-loss-mediated stress reduction plausible; no direct measurement |
| ⚖️ Recovery / Repair | 5.0 | No direct data; weight-loss-mediated joint load reduction positive, protein requirements complicate repair |
| ⚖️ Memory | 4.8 | Observational signal only; no dedicated trial |
| ○ Antioxidant / Oxidative Stress | 4.5 | Indirect via metabolic improvement; no direct antioxidant mechanism |
| ○ Cellular Senescence | 4.5 | Visceral fat reduction lowers SASP signaling; no direct senolytic activity |
| ○ Gut Health / Microbiome | 4.3 | Severe GI side effects (nausea 40-60%, vomiting 15-25%, constipation 15-20%) during titration; gastroparesis signal elevated 3.67x |
| ○ Autophagy | 4.0 | No direct autophagy data; weight loss and caloric restriction activate autophagy indirectly |
| ○ Strength / Power | 3.5 | Strength decreases proportional to lean mass loss; training must intensify to offset |
| ○ Bone / Joint Health | 3.0 | TriNetX real-world: elevated osteoporosis and fracture risk vs other GLP-1s; animal data suggests intrinsic bone-loss mechanism |
Frequently Asked Questions
How does tirzepatide actually work?
Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), producing the 6.5 percentage-point weight-loss superiority over semaglutide observed in SURMOUNT-5 (Wharton 2025). The GLP-1R arm drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying by 50 to 70 percent at steady state, and central appetite suppression. The GIPR arm adds independent CNS satiety signaling, direct effects on adipocyte biology including preadipocyte differentiation into metabolically healthier subcutaneous fat, and counterregulatory glucagon stimulation during hypoglycemia. The dual action is why tirzepatide reduces visceral fat 44 percent vs 3 percent for insulin at 52 weeks (SURPASS-3 MRI substudy, Cusi 2022).
What dose of tirzepatide should I take, and how do I titrate?
The FDA-label titration goes 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg subcutaneously once weekly, advancing every 4 weeks; 15 mg is the SURMOUNT-1 target for maximum weight loss (-20.9 percent at 72 weeks, Jastreboff 2022). The 2.5 mg starter is a tolerability ramp, not a therapeutic dose. Community consensus maintenance sits at 10 to 12.5 mg, not 15 mg, because the 10-to-15 mg curve shows diminishing marginal weight-loss returns with higher GI side effects. Biohacker microdose protocols at 0.125 to 2.5 mg/week for body recomposition are anecdotal with zero RCT support. Accelerated 2-week titration is widely practiced but raises nausea and vomiting rates by approximately 20 to 30 percent vs standard 4-week pacing.
Does tirzepatide work better than semaglutide?
Yes on weight loss by a clinically meaningful 6.5 percentage points at 72 weeks per SURMOUNT-5 (n=751, pooled 10+15 mg tirzepatide -20.2 percent vs semaglutide 2.4 mg -13.7 percent; 31.6 percent vs 16.1 percent achieving ≥25 percent weight loss). SURPASS-2 also showed superior HbA1c reduction in T2D (-2.46 vs -1.86 percentage points at highest doses, n=1,879, Frias 2021). Tirzepatide's edge narrows for cardiovascular outcomes since SURPASS-CVOT showed MACE HR 0.85 vs insulin glargine, while SELECT showed semaglutide MACE HR 0.80 vs placebo in non-diabetic obesity. Tirzepatide wins on weight and glycemia; semaglutide has a more mature cardiovascular and renal evidence base from head-to-head comparisons with placebo.
Is tirzepatide safe for long-term use?
Tirzepatide carries a confirmed catastrophic-risk signal that sets the Safety Risk floor at 4.0: hemorrhagic and necrotizing pancreatitis with fatal post-market cases is an intrinsic listed adverse event (65,974 FAERS reports through Q1 2025; 221 confirmed deaths, 0.3 percent of known-outcome reports, comparable to many chronic pharmaceuticals). Sodhi et al. 2023 JAMA found a 9.09x relative risk for pancreatitis and 3.67x for gastroparesis vs bupropion-naltrexone in weight-loss users. A rodent-derived thyroid C-cell tumor black-box warning applies to all GLP-1 agonists; no confirmed human medullary thyroid carcinoma case in 4 years of wide use, but MTC latency is 10 to 20 years so current post-market data cannot rule it out. Real-world TriNetX cohort data flag elevated osteoporosis and fracture risk vs other GLP-1RAs, a signal not captured in the SURMOUNT/SURPASS trials. Lifetime exposure risk profile is closer to a chronic-disease pharmaceutical than a metabolic supplement.
What happens when I stop tirzepatide?
Weight rebound is rapid and near-complete within a year per SURMOUNT-4 (n=670; after 36 weeks open-label -20.9 percent, the placebo-switched group regained +14 percent body weight over 52 weeks, with 82.5 percent regaining at least 25 percent of lost weight). Community experience reports faster regain cold-stop, up to two-thirds regained within 90 days without tapering, plus ghrelin overshoot above baseline and appetite rebound worse than pre-treatment. Cardiometabolic benefits (HbA1c, blood pressure, lipids) reverse proportionally to weight regain. The mechanism is suppression, not reprogramming: tirzepatide manages a chronic physiology while on board, it does not reset it. This is the single biggest trade-off in the scorecard and the reason durability anchors at 1.5 of 5.
Who should absolutely avoid tirzepatide?
Six populations should not take tirzepatide. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is an absolute contraindication per the boxed warning. Prior pancreatitis of any etiology, severe gastroparesis, or active inflammatory bowel disease are absolute. Pregnancy and planned pregnancy require discontinuation at least 2 months before conception (skeletal malformations in rats, fetal growth reduction in rabbits). Type 1 diabetes is not an approved indication and combination with insulin demands 25 percent insulin reduction to avoid severe hypoglycemia. Oral contraceptive users must switch to non-oral methods because tirzepatide reduces OC peak concentration 59 to 66 percent via delayed gastric emptying, causing contraceptive failure. Concurrent sulfonylureas require dose reduction; concurrent warfarin destabilizes INR.
Mounjaro vs Zepbound vs compounded tirzepatide: which should I get?
Mounjaro and Zepbound are the same molecule; Mounjaro is approved for T2D, Zepbound for obesity and obstructive sleep apnea, both from Eli Lilly, retail $1,000 to $1,300 per month without insurance. LillyDirect (direct-to-consumer Lilly program, $299 to $499 per month for vial formulations) has become the pragmatic biohacker option since the FDA ended the compounding shortage exemption in February to March 2025. Compounded 503A tirzepatide from licensed pharmacies remains a legal gray area; Lilly independent testing identified high impurity levels in compounded samples. Gray-market research peptides from Chinese suppliers sell for under $100 per month but independent third-party testing shows approximately 70 percent contamination or under-dosing rates. Supply-chain contamination is extrinsic risk, not reflected in the dimension scores but critically important in real-world outcomes.
How do I preserve muscle mass on tirzepatide?
Approximately 25 percent of weight lost on tirzepatide is lean mass without resistance training per the SURMOUNT-1 DEXA subset (10.9 percent absolute lean mass loss from baseline), dropping to roughly 18 percent with resistance training per small studies and community-reported protocols. The mitigation stack widely used in the biohacker community: 1.8 to 2.4 g/kg body weight protein daily (higher than standard recommendations because of the caloric deficit), resistance training 3 to 5 sessions per week prioritizing compound lifts, creatine monohydrate 5 g/day, and HMB 3 g/day. Nickerson 2023 demonstrated that adequate protein plus progressive overload attenuates the lean-mass-loss curve during GLP-1 therapy. Without this stack, the risk is sarcopenic obesity, especially in adults over 50, and the real-world TriNetX cohort confirms elevated osteoporosis signal suggesting bone loss may compound the muscle issue.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| SURMOUNT-5 successor study confirms long-term (≥5 year) tirzepatide superiority on mortality | Evidence 4.5→4.8, Durability 1.5→2.0 | 6.3 / 10 👍 Worth trying |
| Independent non-Lilly Phase 3 replicates key weight/HbA1c findings at ≥2,000 enrolled | Evidence 4.5→4.8 | 6.1 / 10 👍 Worth trying |
| Validated maintenance-dose taper protocol shows ≤10% regain at 2 years post-target | Durability 1.5→3.0, Dependency 4.0→3.3 | 6.9 / 10 👍 Worth trying (near Strong) |
| Human medullary thyroid carcinoma signal emerges in 10-year post-market data | Safety 4.0→4.8, Reversibility 2.3→3.2 | 5.3 / 10 ⚖️ Neutral |
| Oral tirzepatide approved with equivalent efficacy and improved titration tolerance | Effort 1.8→1.2, Side Effects 3.3→2.7 | 6.3 / 10 👍 Worth trying |
| AUD (alcohol use disorder) indication approved after Phase 3 RCTs in non-obese drinkers | Breadth 4.7→5.0, Bioindividuality 4.5→4.7 | 6.2 / 10 👍 Worth trying |
Key Evidence Sources
- Jastreboff AM, Aronne LJ, Ahmad NN et al. 2022, NEJM. SURMOUNT-1: 72-week RCT, n=2,539, non-diabetic obesity. Mean weight loss -20.9% at 15 mg vs -3.1% placebo. 57% achieved ≥20% weight loss at 15 mg.. Flagship weight-loss RCT; defines the obesity indication
- Wharton S, Davies M, Dicker D et al. 2025, NEJM Evidence. SURMOUNT-5: head-to-head vs semaglutide 2.4 mg, n=751. Tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.. Definitive head-to-head showing tirzepatide weight-loss superiority
- Aronne LJ, Sattar N, Horn DB et al. 2023, JAMA. SURMOUNT-4: 88-week withdrawal trial. Placebo switch regained +14% body weight; 82.5% regained ≥25% of lost weight.. Rebound/durability evidence; the core 'chronic therapy' argument
- Frias JP, Davies MJ, Rosenstock J et al. 2021, NEJM. SURPASS-2: tirzepatide vs semaglutide 1.0 mg, n=1,879 T2D. HbA1c -2.46 vs -1.86 pp at highest doses; weight -11.2 vs -5.7 kg.. T2D head-to-head vs semaglutide
- Lilly Investors 2024, SURPASS-CVOT. n=13,884 T2D + CV risk, 3.4 years median. MACE HR 0.85 vs insulin glargine (p=0.026); HF hospitalization HR 0.71; all-cause mortality HR 0.87.. First positive CV outcomes trial for tirzepatide
- Loomba R, Abdelmalek MF, Armstrong MJ et al. 2024, NEJM. SYNERGY-NASH: biopsy-confirmed MASH, n=190. MASH resolution 62% at 15 mg vs 10% placebo; fibrosis ≥1 stage improvement 51%.. Histologic MASH outcome trial
- Malhotra A, Grunstein RR, Fietze I et al. 2024, NEJM. SURMOUNT-OSA: moderate-to-severe OSA, n=469. AHI -25.3 events/hour; 51.5% resolution of moderate-severe OSA in non-PAP arm.. Sleep apnea indication basis
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. 2023, JAMA. Real-world cohort of GLP-1RAs for weight loss. Pancreatitis RR 9.09; gastroparesis RR 3.67; bowel obstruction RR 4.22 vs bupropion-naltrexone.. Critical real-world adverse event signal; drove FDA label update
- Cusi K, Sattar N, García-Pérez LE et al. 2022, Lancet Diabetes & Endocrinology. SURPASS-3 MRI substudy. Visceral fat -44%, liver fat -8.4 pp, subcutaneous fat -25% vs insulin degludec +3%.. Body composition and liver fat imaging data
- Rosenstock J, Wysham C, Frías JP et al. 2021, Lancet. SURPASS-1 monotherapy T2D, n=478. HbA1c -2.07 pp at 15 mg; 96% reached HbA1c <7%; weight -9.5 kg.. Monotherapy T2D efficacy foundation
- Ludvik B, Giorgino F, Jódar E et al. 2021, Lancet Diabetes & Endocrinology. SURPASS-3: tirzepatide vs insulin degludec, n=1,444. Weight -12.9 kg vs +2.3 kg; net difference -15.2 kg.. Weight-neutrality vs insulin comparator
- Garvey WT, Frias JP, Jastreboff AM et al. 2023, Lancet. SURMOUNT-2: T2D + obesity, n=938, 72 weeks. Weight -15.7% at 15 mg; HbA1c -2.17 pp.. T2D obesity crossover population
- Wadden TA, Chao AM, Machineni S et al. 2023, Nature Medicine. SURMOUNT-3: lifestyle lead-in plus tirzepatide. Total -26.2% weight loss from study entry.. Lifestyle + drug additive effect
- Shi Q, Wang Y, Hao Q et al. 2022, Frontiers in Endocrinology. Meta-analysis of 5 tirzepatide RCTs in T2D, n=6,609. All 3 doses superior on HbA1c and weight vs all comparators.. T2D meta-analysis anchor
- Dahl D, Onishi Y, Norwood P et al. 2022, JAMA. SURPASS-5: added to insulin glargine, n=475. HbA1c -2.40 pp at 10 mg added; -8.8 kg weight at 15 mg.. Combination with basal insulin
Other interventions for Blood Sugar
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.325 − 3.068 = 0.257
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((0.257 + 7) / 12) × 10 = 6.0 / 10
Further learning
13 Top Peptides Companies Review & Test 2026: Where I Buy Peptides Online
After a decade in the peptide industry, I reviewed and ranked 13 reputable peptide companies across two tiers. Your source can mean the difference…
Fat Loss Peptides & Fasting: Body Recomposition Plan
Uncover the tools in Jay Campbell's new book “30 Days to Shredz.” Discover the power of intermittent fasting and performance enhancers for rapid fat…
